59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 61-62

Background

Clinical research participants are too often not representative of populations most affected by cancer or those with the highest burden of disease. Women of color are underrepresented in surgical oncology research. Miami offers a unique population as a majority-minority city, which allows greater sampling of underrepresented groups. Through a feasibility analysis of an ongoing study, we sought to challenge the historical dogma that non-White or non-English–speaking patients are less likely to agree to participate in surgical research.

Methods

Women undergoing breast surgery were approached to participate in a prospective study. Our primary outcome was “consent to participate” and secondary outcome was willingness to participate in future microbiome research. Data description and analysis were performed (SAS vs 27.0.1.0).

Results

Selected Characteristics as Proportions of the Race/Ethnicity/Language Group

Selected Characteristics as Proportions of the Race/Ethnicity/Language Group

Univariate models showed that non-White (OR, 1.318; 95% CI, 0.378-4.588) or Hispanic (OR, 1.978; 95% CI, 0.784-4.989) patients were not more likely to decline to participate than their White counterparts. The combined minority (non-White, non-Hispanic) model showed an increased likelihood of participating (OR, 95%). Multivariate analysis showed similar results while controlling for age and language. Univariate analysis for our second outcome showed that patients who are a minority are less likely to participate in future microbiome clinical research compared with their White counterparts (OR, 95%), but Hispanic patients are more likely to participate in future microbiome clinical research compared to their White counterparts (OR, 95%).

Conclusion

Non-White, non-Hispanic patients are more likely to participate in surgical research, and most patients in our diverse cohort would continue to participate in microbiome research. By ensuring they are actively included in clinical trials, we can continue to elucidate differences in presentation and lessen discrepancies in treatment. All eligible patients should be approached to be included in clinical trials regardless of race, ethnicity, or primary language and without the assumption that they will decline to participate.

Articles in this issue

52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left  Breast Cancer
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast  Cancer in the United States by Palliative Care Utilization
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer in the United States by Palliative Care Utilization
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30
62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population
62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population
63 Choice Architecture Bias in Genetic Counseling of Breast Cancer Patients
63 Choice Architecture Bias in Genetic Counseling of Breast Cancer Patients
64 Empowering Medical Students to Deliver Breast Health Education:  A Community-Based Initiative
64 Empowering Medical Students to Deliver Breast Health Education: A Community-Based Initiative
65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices
65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices
66 A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the  PREDICT Study
66 A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table